# Junta clínica — PT-pseudo_394e0b8dbeeb (tarea 1)

## Intervención 1 — INTAKE

*the record clerk; reads the file out loud and interprets nothing* · vuelta 1

Colleagues, this is the record as it arrived, field by field. I read it out and interpret nothing; everything after this is yours.

{
  "case_id": "PT-pseudo_394e0b8dbeeb",
  "pid": "PT-pseudo_394e0b8dbeeb",
  "task": 1,
  "psa": 9.2,
  "age": 71,
  "months": 3,
  "pirads": "4",
  "psad": 0.17,
  "psav": 1.1,
  "psap": 10.1,
  "vol": 53.0,
  "dre": "Nodus",
  "bx": "Negative",
  "cspca": 0.78939086,
  "medhx": "Hypercholesterolaemia, Coronary artery disease, Obesity (BMI >30), Benign prostatic hyperplasia",
  "meds": "atorvastatin, simvastatin, rosuvastatin, aspirin 80 mg, metoprolol, tamsulosin",
  "notes": "PSA 9.2 ng/mL. PI-RADS 4. PSAD 0.17. Prostate volume 53 mL. DRE nodus. csPCa 0.79.",
  "pmhx": [
    "Hypercholesterolaemia",
    "Coronary artery disease",
    "Obesity (BMI >30)",
    "Benign prostatic hyperplasia"
  ],
  "allergies": [],
  "vitals": {
    "weight": "93 kg",
    "height": "164 cm",
    "bmi": "34.6",
    "bp": "114/71 mmHg",
    "hr": "70 bpm",
    "smoking": "Current smoker (45 pack-yr)",
    "last_dental": "2 yr ago",
    "flu_vax": "Oct 2024"
  },
  "enc_dept": "Urology - outpatient",
  "enc_date": "04 Jan 2025",
  "enc_ref": "Dr. E. Mulder (GP)",
  "enc_type": "Re-evaluation - prior negative biopsy",
  "note_sections": [
    {
      "s": "Chief complaint",
      "t": "Elevated PSA progression alongside a newly identified PI-RADS 4 lesion on multiparametric MRI has necessitated specialist re-assessment."
    },
    {
      "s": "History",
      "t": "Mr X, a 71-year-old harbour pilot (semi-retired), entered initial evaluation in early 2023 following an incidental PSA elevation. Lower urinary tract symptoms remain mild and are currently managed with tamsulosin, yielding an IPSS score of 7. He reports no haematuria or acute urinary retention. Cardiovascular comorbidities encompass coronary artery disease and hypercholesterolaemia, managed through a regimen of atorvastatin, simvastatin, rosuvastatin, aspirin 80 mg, and metoprolol. He is a Current smoker (45 pack-yr) but maintains physical activity by cycling roughly 30 kilometres three times weekly. Obesity (BMI >30) is present. He remains married and lives with his partner. An adult daughter handles his medical correspondence upon request. Aside from the urological investigations, he experiences stable bilateral knee discomfort stemming from years of deck work and recently visited a podiatrist for routine nail care. No systemic symptoms or unexplained weight loss are reported."
    },
    {
      "s": "Physical examination",
      "t": "DRE — prostate: asymmetrically enlarged, firm texture, discrete nodule palpable in the right mid-gland. General examination remains unremarkable, with stable vital signs and no evidence of palpable lymphadenopathy or abdominal masses."
    }
  ],
  "occupation": "harbour pilot (semi-retired)",
  "marital": "Married",
  "living": "Lives with partner",
  "next_of_kin": "Adult son (primary contact)",
  "recent_other": [
    "Podiatry — routine foot care"
  ],
  "alcohol": "8 units / week",
  "exercise": "Cycling 3x/week, ~30 km",
  "ipss": "IPSS score: 7/35 (mild LUTS)",
  "admin": "Daughter manages communication; CC on letters with patient consent.",
  "mri_hospital": "Jeroen Bosch Ziekenhuis ('s-Hertogenbosch)",
  "ct": null,
  "active_treatment_flag": 0
}

## Intervención 2 — INTAKE

*the record clerk; reads the file out loud and interprets nothing* · vuelta 1

And this is the same record as the reading form presents it — the panel the urologist sees up front, with the masked documents named but not shown.

You are a senior urologist reviewing a patient case. The structured clinical
record below is shown to you up front, exactly as in the reading form. Some
documents are not shown and must be pulled up via the available tools
(radiology / MRI report, pathology report, previous notes, laboratory
results, PSA history, and the family-history anamnesis) when you need to
consult them.

Case ID: PT-pseudo_394e0b8dbeeb
Task: 1

Encounter: Urology - outpatient on 04 Jan 2025.
Referrer: Dr. E. Mulder (GP).
Type: Re-evaluation - prior negative biopsy.

Clinical data (read-only — values loaded from the record):
  - 71-year-old male
  - PSA: 9.2 ng/mL
  - mpMRI — PI-RADS score: 4 (1–2 low · 3 equivocal · 4–5 high risk)
  - PSA density: 0.17 ng/mL²
  - PSA velocity: 1.1 ng/mL/yr
  - Prior PSA: 10.1 ng/mL
  - Prostate volume: 53.0 mL
  - Months since last PSA: 3
  - DRE findings: Nodus (Normal · Nodus · Benign · Suspicious · Abnormal · Negative · Not done)
  - Prior biopsy: Negative (None · Negative · ASAP/HGPIN · Positive)
  - csPCa predicted probability: 0.78939086 (clinically significant PCa = ISUP ≥ 2)

Medical history & medication:
  - Medical history: Hypercholesterolaemia, Coronary artery disease, Obesity (BMI >30), Benign prostatic hyperplasia
  - Problem list / PMHx: Hypercholesterolaemia, Coronary artery disease, Obesity (BMI >30), Benign prostatic hyperplasia
  - Current medication: atorvastatin, simvastatin, rosuvastatin, aspirin 80 mg, metoprolol, tamsulosin
  - Allergies: NKA
  - Additional notes: PSA 9.2 ng/mL. PI-RADS 4. PSAD 0.17. Prostate volume 53 mL. DRE nodus. csPCa 0.79.

Vitals: weight 93 kg, height 164 cm, BMI 34.6, BP 114/71 mmHg, HR 70 bpm. Smoking: Current smoker (45 pack-yr).

Chief complaint: Elevated PSA progression alongside a newly identified PI-RADS 4 lesion on multiparametric MRI has necessitated specialist re-assessment.

History: Mr X, a 71-year-old harbour pilot (semi-retired), entered initial evaluation in early 2023 following an incidental PSA elevation. Lower urinary tract symptoms remain mild and are currently managed with tamsulosin, yielding an IPSS score of 7. He reports no haematuria or acute urinary retention. Cardiovascular comorbidities encompass coronary artery disease and hypercholesterolaemia, managed through a regimen of atorvastatin, simvastatin, rosuvastatin, aspirin 80 mg, and metoprolol. He is a Current smoker (45 pack-yr) but maintains physical activity by cycling roughly 30 kilometres three times weekly. Obesity (BMI >30) is present. He remains married and lives with his partner. An adult daughter handles his medical correspondence upon request. Aside from the urological investigations, he experiences stable bilateral knee discomfort stemming from years of deck work and recently visited a podiatrist for routine nail care. No systemic symptoms or unexplained weight loss are reported.

Physical examination: DRE — prostate: asymmetrically enlarged, firm texture, discrete nodule palpable in the right mid-gland. General examination remains unremarkable, with stable vital signs and no evidence of palpable lymphadenopathy or abdominal masses.

Patient info: harbour pilot (semi-retired); Married; Lives with partner.
Next of kin: Adult son (primary contact).

Lifestyle: alcohol 8 units / week; exercise Cycling 3x/week, ~30 km; IPSS score: 7/35 (mild LUTS).

Recent other appointments: Podiatry — routine foot care.
Admin: Daughter manages communication; CC on letters with patient consent.

Information you can request via tools (the masked "Extended EHR view" — what
the urologist would actively pull up during the consult):
  - radiology / MRI report (full mpMRI prose behind the headline imaging values)
  - pathology report (any prior biopsy on record)
  - previous GP / urology consultation notes
  - laboratory results (full panel)
  - PSA history (trend / velocity beyond the headline value)
  - family history of prostate cancer (anamnesis)

Question:
Based on this patient's data, do you recommend biopsy?


One correction to that last paragraph before anybody acts on it: the documents this task actually serves are radiology_report, psa_trend, previous_notes, laboratory_results, plus the family-history anamnesis. There is NO pathology report to pull up in a task-1 biopsy decision — the prior-biopsy status on the panel above is all the pathology on record, and whatever the previous notes say about it. Nobody should ask for one, and nobody should quote one.

## Intervención 3 — EXPERT-STRUCTURED

*Expert 1, Extra-Trees on the structured panel only; opening bid with an error bar* · vuelta 1

Expert 1 here — the classifier that reads the structured panel and nothing else. My bid:

SUGGESTION: BIOPSY   p(biopsy) = 0.79
  uncertainty  +/- 0.06 epistemic (95% band 0.68-0.90); among patients I cannot tell apart the outcome was 0.74 of 1.00 mixed
  reliability  HIGH ('firm' tier) — out-of-fold it was right 88% of the time over the 33 labelled cases in this tier

What moved me most, across the labelled series: prior positive biopsy, PI-RADS >= 4, no prior biopsy, pmhx_hypercholesterolaemia, suspicious DRE, number of comorbidities. I read 39 variables, all
from the panel — nothing from the mpMRI prose, the PSA trajectory, the previous notes or the
laboratory. Out-of-fold over 91 labelled cases: AUC 0.758, balanced
accuracy 0.625.

The final call is the chair's.

## Intervención 4 — EXPERT-COHORT

*cohort criterion; what the labelled series did in this exact situation* · vuelta 1

This patient's situation: prior negative biopsy. My criterion answers BIOPSY.

The criterion: repeat, targeted, when the mpMRI shows a PI-RADS 4-5 lesion; do not repeat a negative biopsy for an unchanged PI-RADS 3 or lower picture. In the labelled series this criterion matched the reading urologist in 16 of 18 cases in exactly this situation.

Like Expert 1, I have read ONLY the visible panel — not the mpMRI prose, the PSA trajectory, the
previous notes or the laboratory panel. Departing from me needs a specific finding from a document
somebody actually opened, named out loud; not a restatement of the panel numbers I already used.

## Intervención 5 — EXPERT-LIBRARY

*case library; the closest labelled precedents and what the reading urologist did with them* · vuelta 1

The case library holds 17 labelled men in this same situation (Negative prior biopsy). The 3 closest by panel distance, and what the reading urologist did:
  1. distance 1.41: PI-RADS 4, PSA 12.0, PSAD 0.313, age 73, DRE Not done -> BIOPSY (clear). He wrote: "P4 in 73 year old patient."
  2. distance 1.95: PI-RADS 4, PSA 6.0, PSAD 0.08, age 67, DRE Normal -> BIOPSY (clear). He wrote: "P4 lesion in 67 year old patient."
  3. distance 1.97: PI-RADS 4, PSA 34.7, PSAD 0.352, age 66, DRE Nodus -> BIOPSY (uncertain). He wrote: "New (? -> no earlier MRI report available) PIRADS 4 with high PSA-density needs biopsy"

PRECEDENT: BIOPSY (weighted vote 1.00 for biopsy). Distance-weighted precedent is fair here (0.78 leave-one-out).

What the precedents are FOR: they show what this urologist looks at and how he phrases the call. What they are NOT: facts about this patient. Nobody may cite a precedent's grade, PSA or MRI as if it were his.

## Intervención 6 — EXPERT-TRACE

*Expert 4, trace model; which documents the reading urologist opens and what he weighs in this situation* · vuelta 1

Expert 4 here — the model of how the reading urologist works a case like this. Predicted from his 17 labelled traces in this situation (Negative prior biopsy): a per-field model where it beats the mode out of fold (prior-biopsy weight, DRE weight, PI-RADS weight, and whether he opens the laboratory), the mode elsewhere.

WHAT HE OPENS: radiology_report, psa_trend, previous_notes, laboratory_results.
WHAT HE WEIGHS: bx=important, fh=noted, age=important, dre=important, psa=important, vol=noted, psad=noted, pirads=important, comorbidity=noted.
HOW SURE HE USUALLY IS: clear.

MODERATOR: that list of documents is the plan — exactly those, no more. Every document opened beyond what
he would open is scored against the conference as an unnecessary reveal; every document left closed
leaves a variable he weighed without its source. Attach the question each one must answer.

## Intervención 7 — EXPERT-EAU

*EAU guideline specialist; speaks only from the guideline text he retrieved* · vuelta 1

GUIDELINE
The EAU guidelines state that a repeat biopsy after a negative systematic biopsy should be considered dependent on risk factors such as PSA density, PSA velocity, and the PI-RADS score. The guideline suggests that low PSA-D (< 0.15 ng/mL/cc) and low PSA velocity (PSAV) may be factors to consider excluding a repeat biopsy.

WHAT THE EXPERTS' BIDS DO NOT SETTLE
Expert 1's suggestion of biopsy is not settled by the guideline because the guideline makes the decision dependent on specific laboratory values like PSA density and PSA velocity. Expert 1's reliance on comorbidities and DRE findings does not satisfy the guideline's requirement for these specific quantitative metrics.

WHAT WE STILL NEED
The guideline requires the PSA density and PSA velocity to determine the decision.
PSA density is 0.17 ng/mL/cc, which is above the threshold of 0.15 ng/mL/cc mentioned in the retrieved text.
PSA velocity is 1.1 ng/mL/yr, which is not explicitly compared against a threshold in the retrieved text.
The prior biopsy status is Negative, which is a known fact on the panel, which is a factor the guideline makes decisive.

## Intervención 8 — MODERATOR

*chairs the discussion; sets the open questions and assigns the documents* · vuelta 1

This case hinges on whether the quantitative metrics from the laboratory results, specifically PSA density and velocity, meet the EAU guideline thresholds for excluding a repeat biopsy.

The documents for this session were fixed by EXPERT-TRACE; what I add is the question each one has to answer, and the open questions for the room.

REGISTRAR — pull these up, and answer exactly the question attached to each:
  radiology_report (get_mri_report) -> What is the lesion size and zone of the PI-RADS 4 lesion?
  psa_trend (get_psa_trend) -> What is the serial PSA value trend beyond the headline number?
  previous_notes (get_previous_notes) -> What was the GRADE (Gleason or ISUP) of the prior negative biopsy, and is a surveillance protocol in place?
  laboratory_results (get_lab_results) -> What are the full panel results, specifically free-PSA fraction and renal function?

OPEN QUESTIONS for this conference — these are what the decision hangs on:
  Q1. Does the PSA density of 0.17 ng/mL/cc, as per the laboratory results, meet the EAU guideline threshold of < 0.15 ng/mL/cc for excluding a repeat biopsy?
  Q2. How should the PSA velocity of 1.1 ng/mL/yr be interpreted in the context of the EAU guideline regarding repeat biopsy decisions?

## Intervención 9 — REGISTRAR

*the registrar who pulls up documents; reports what they say, nothing else* · vuelta 1

WHAT I FOUND
radiology_report
Subject: Multiparametric MRI Prostate | Date: 20 December 2024 | Institution: Jeroen Bosch Ziekenhuis ('s-Hertogenbosch)
What is the lesion size and zone of the PI-RADS 4 lesion?
The 12 mm hypointense focus is within the right mid-gland, reaching toward the peripheral zone.

psa_trend
What is the serial PSA value trend beyond the headline number?
The serial PSA values are: "Apr 2023, 7.0", "Nov 2023, 7.9", "Jun 2024, 6.5", "Jan 2025, 9.2".

previous_notes
What was the GRADE (Gleason or ISUP) of the prior negative biopsy, and is a surveillance protocol in place?
The GRADE of the prior negative biopsy is "Negative (None · Negative · ASAP/HGPIN · Positive)". There is no surveillance protocol mentioned.

laboratory_results
What are the full panel results, specifically free-PSA fraction and renal function?
Free PSA is "1.44 ng/mL", and the %Free PSA is "16%". eGFR is ">60 mL/min/1.73m2".

WHAT I DID NOT OPEN
family-history anamnesis, because the information was not required to answer the open questions.

WHAT THIS SUPPORTS
Findings that argue FOR sampling this patient now:
PI-RADS 4 lesion identified on mpMRI.
PSA density of 0.17 ng/mL/mL.

Findings that argue AGAINST sampling this patient now:
Nothing.

WHERE THIS LEANS
The quantitative lab data suggests that the PSA density metric does not meet the EAU threshold for excluding a repeat biopsy, leaning towards biopsy.
LEAN: biopsy

## Intervención 10 — EXPERT-PSA

*Expert 2, PSA projector; the trajectory behind the headline PSA, with a conformal band* · vuelta 1

Expert 2 here — the PSA projector. I read only the serial PSA the registrar opened.

TRAJECTORY: RISING (borderline). Last value 9.20 ng/mL over 4 points spanning 21 months; velocity +0.89 ng/mL per year; doubling time about 78 months.
PROJECTION at 6 months: 14.3 ng/mL, conformal 95% band 4.1-49.8.

Read the band before the point: it is wide by construction, and I only call a direction when the whole
band clears the last value. This does not vote on the biopsy — a rising PSA in a man with a known
diagnosis is the disease behaving as known — it tells the chair how fast the number is moving.

## Intervención 11 — EXPERT-FUSION

*Expert 3, Extra-Trees on panel + laboratory + MRI prose; speaks only on documents that were opened* · vuelta 1

Expert 3 here — the fusion classifier. I read the panel, the mpMRI report and the laboratory panel; nothing from the previous notes or the PSA series.

SUGGESTION: BIOPSY   p(biopsy) = 0.77
  uncertainty  +/- 0.05 epistemic (95% band 0.67-0.87), of which 0.00 comes from values that had to be imputed
  reliability  HIGH ('firm' tier) — out-of-fold it was right 86% of the time over the 36 labelled cases in this tier

What moved me most across the labelled series: prior positive biopsy, no prior biopsy, free PSA < 15%, DWI restriction in the report, lesion >= 15 mm in the report, suspicious DRE. Out-of-fold AUC 0.794. I am the only expert that has read the report's wording, and I still cannot see the prior grade or the
surveillance history: those are in the notes, and the registrar has to carry them.

## Intervención 12 — PANEL-PROTOCOL

*the panel's written protocol; consolidates the experts by rule and says which rule fired* · vuelta 1

The panel protocol, applied to what is on the board:

  EXPERT-STRUCTURED  BIOPSY, p(biopsy)=0.79  ('firm' tier)
  EXPERT-FUSION      BIOPSY, p(biopsy)=0.77  ('firm' tier, fusion_full)
  EXPERT-LIBRARY     BIOPSY, p(biopsy)=1.00  (k=3 precedents)
  EXPERT-COHORT      BIOPSY  (rule pirads_ge_4)

  documented prior grade in the opened documents: none recorded

RULE THAT FIRED: cohort criterion (pirads_ge_4) — carried by EXPERT-COHORT.
PANEL ANSWER: BIOPSY. It matched the reading urologist in 16 of 18 labelled cases in exactly this situation (prior negative biopsy).

Confidence the trace model expects here: clear. Weights it expects: bx=important, fh=noted, age=important, dre=important, psa=important, vol=noted, psad=noted, pirads=important, comorbidity=noted.

CHAIR: this is the panel's position. You sign it, and you write why in the room's words — naming what the registrar retrieved. If you believe a retrieved finding overturns it, name that finding with its value; the burden is on the finding, not on the panel.

## Intervención 13 — VERIFIER

*second EAU reader; checks against the guideline whether this can be decided yet* · vuelta 1

SUFFICIENCY
The documents opened by the registrar—radiology_report, psa_trend, previous_notes, and laboratory_results—directly address the moderator's questions regarding PSA density and PSA velocity, as these values are present in the retrieved data.

ALIGNMENT WITH THE PANEL
The retrieved finding regarding PSA density (0.17 ng/mL/cc) supports the PANEL-PROTOCOL's decision to proceed with biopsy, as it is above the EAU exclusion threshold of < 0.15 ng/mL/cc.

THE OPEN QUESTIONS, ONE BY ONE
Q1. The laboratory results show a PSA density of 0.17 ng/mL/cc, which is above the EAU guideline threshold of < 0.15 ng/mL/cc for excluding a repeat biopsy.
Q2. The PSA velocity of 1.1 ng/mL/yr is not explicitly interpreted against a threshold in the retrieved EAU text, leaving this interpretation unaddressed by the guideline itself.

WHAT CARRIES WEIGHT, AND WHY
The PSA density (0.17 ng/mL/cc) is highly relevant as it directly compares to the EAU threshold for excluding biopsy. The PI-RADS 4 finding from the radiology report is also critical, as it is the primary driver for the cohort criterion that led to the panel's decision.

MY SUGGESTION TO THE CHAIR
Based on the retrieved data, the quantitative lab data suggests that the PSA density metric does not meet the EAU threshold for excluding a repeat biopsy, leaning towards biopsy.

VERDICT: ready | SUGGEST: biopsy | MISSING: none

[The conference closes after pass 1: the verifier called the record ready. The chair decides on the record as it stands.]

## Intervención 14 — CHAIR

*the senior urologist who signs the decision* · vuelta 1

MY DECISION: BIOPSY   (confidence: clear)

Given the patient has a prior negative biopsy and a new PI-RADS 4 lesion identified on MRI, the cohort criterion strongly supports proceeding with a repeat biopsy. This decision is further supported by the laboratory finding that the PSA density of 0.17 ng/mL/cc exceeds the EAU exclusion threshold. The evidence converged on the need for further tissue sampling to evaluate the high-risk lesion.

What carried weight: bx=important, age=important, dre=important, psa=important, vol=noted, psad=noted, pirads=important, comorbidity=noted
Documents this conference opened: radiology_report, psa_trend, previous_notes, laboratory_results
